Scholarlink

Background <p>Steroid-refractory (SR) acute graft-versus-host disease (aGVHD) is the major cause of early mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Xenopax, a novel and the only available humanized interleukin-2 (IL-2) receptor antagonist, has been approved as a category 2 biological product by the National Medical Products Administration. This study aims to evaluate the efficacy, safety, and prognostic factors of xenopax treatment for SR-aGVHD in real-world settings.</p> Methods <p>This was a multicenter, retrospective analysis that included SR-aGVHD patients who received xenopax at 17 hospitals across China. The data were collected from the electronic medical records in transplant databases. The primary endpoint was the 28-day overall response rate (ORR), encompassing both partial and complete responses. This study also included independent historical SR-aGVHD cohorts treated with best available treatments (BATs, <i>n</i> = 1009) as controls.</p> Results <p>In total, 172 SR-aGVHD patients were included in this study. Xenopax was administered either as monotherapy (<i>n</i> = 60) or in combination with other second-line treatments (<i>n</i> = 112). The ORR was 64.5% [95% confidence interval (CI) 57.3–71.7%] on day 28 and 82.6% (95% CI 76.9–88.3%) at any time after xenopax treatment. The 2-year probabilities of disease-free survival, overall survival, non-relapse mortality (NRM), and relapse after xenopax treatment were 57.0% (95% CI 49.9–65.0%), 68.0% (95% CI 61.4–75.4%), 24.2% (95% CI 18.0–30.9%), and 19.0% (95% CI 12.8–25.2%), respectively. The ORR and survival were similar between patients with and without prior second-line treatments. The conditioning regimen and human leukocyte antigen disparity did not impact the efficacy of xenopax treatment. According to the multivariate analysis, the presence of grade III–IV aGVHD did not adversely affect the therapeutic response or survival. Xenopax also showed some superiority over BATs in historical cohorts.</p> Conclusions <p>Our real-world findings suggest that xenopax is an effective and safe treatment for SR-aGVHD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Xenopax for the treatment of steroid-refractory acute graft-versus-host disease: the RELAX study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月29日

查看全文
  • Le-Qing Cao,
  • Wen-Xuan Huo,
  • Er-Lie Jiang,
  • Yue-Wen Fu,
  • Xiao-Jun Xu,
  • Ping-Chong Lei,
  • Ming-Feng Zhao,
  • Zhi Chen,
  • Shu-Xia Guo,
  • Xiao-Bing Huang,
  • Yan-Ming Zhang,
  • Xian-Jing Wang,
  • Guan-Chen Bai,
  • Feng-Bo Jin,
  • Qing-Sheng Li,
  • Ming-Yang Deng,
  • Hao Zhang,
  • Xin-Feng Wang,
  • Xiao-Jun Huang,
  • Xiao-Dong Mo

摘要

Background

Steroid-refractory (SR) acute graft-versus-host disease (aGVHD) is the major cause of early mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Xenopax, a novel and the only available humanized interleukin-2 (IL-2) receptor antagonist, has been approved as a category 2 biological product by the National Medical Products Administration. This study aims to evaluate the efficacy, safety, and prognostic factors of xenopax treatment for SR-aGVHD in real-world settings.

Methods

This was a multicenter, retrospective analysis that included SR-aGVHD patients who received xenopax at 17 hospitals across China. The data were collected from the electronic medical records in transplant databases. The primary endpoint was the 28-day overall response rate (ORR), encompassing both partial and complete responses. This study also included independent historical SR-aGVHD cohorts treated with best available treatments (BATs, n = 1009) as controls.

Results

In total, 172 SR-aGVHD patients were included in this study. Xenopax was administered either as monotherapy (n = 60) or in combination with other second-line treatments (n = 112). The ORR was 64.5% [95% confidence interval (CI) 57.3–71.7%] on day 28 and 82.6% (95% CI 76.9–88.3%) at any time after xenopax treatment. The 2-year probabilities of disease-free survival, overall survival, non-relapse mortality (NRM), and relapse after xenopax treatment were 57.0% (95% CI 49.9–65.0%), 68.0% (95% CI 61.4–75.4%), 24.2% (95% CI 18.0–30.9%), and 19.0% (95% CI 12.8–25.2%), respectively. The ORR and survival were similar between patients with and without prior second-line treatments. The conditioning regimen and human leukocyte antigen disparity did not impact the efficacy of xenopax treatment. According to the multivariate analysis, the presence of grade III–IV aGVHD did not adversely affect the therapeutic response or survival. Xenopax also showed some superiority over BATs in historical cohorts.

Conclusions

Our real-world findings suggest that xenopax is an effective and safe treatment for SR-aGVHD.